Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01205815 · ClinicalTrials.gov registry record
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
A clinical trial of Melanoma, sponsored by Vanderbilt-Ingram Cancer Center.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT01205815: Recruiting study of Melanoma, sponsored by Vanderbilt-Ingram Cancer Center.
NCT01205815 is a study of Melanoma that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 3,000 participants, above the 695-participant average among 266 other Melanoma trials with a reported enrollment target (332% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01205815, a study of Melanoma, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.
Primary Outcome
Tissue is collected upon consent or upon receipt of parafin block, primary aim will be met when all tissues are collected and analyzed at conclusion of study. Intent is to aid patients and their treating physician when making treatment decisions.
Conditions Studied
Interventions
- OTHER Tissue and blood collection
Study Locations (1)
Tennessee
- Vanderbitl-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2010-06-03 |
| Est. Completion | 2027-06 |
What NCT01205815 shows while recruiting
NCT01205815 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 695-participant average among 266 other Melanoma trials with a reported enrollment target (332% higher).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Tissue and blood collection is the first listed.
NCT01205815 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT01205815 about?
NCT01205815 is a clinical study titled "Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment". The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.
What is the current status of trial NCT01205815?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2010-06-03. Estimated completion is 2027-06.
What conditions does trial NCT01205815 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT01205815?
The interventions under investigation include: Tissue and blood collection (OTHER).
Who is sponsoring clinical trial NCT01205815?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01205815 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01205815's enrollment target sits among peer trials
3,000 8th of 266 higher than 258 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI